Biosyent (RX) AI Stock Analysis

• Market Cap: C$118.04M
• Dividend Yield: 1.8%
• Average Volume (3M): 4.61K
• Price to Earnings (P/E): 16.4
• Beta (1Y): 0.27
• Revenue Growth: 10.89%
• EPS Growth: 16.21%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 64
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.63
• Shares Outstanding: 11,471,121
• 10 Day Avg. Volume: 6,618
• 30 Day Avg. Volume: 4,610
• PEG Ratio: 1.01
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.74
• Price to Cash Flow (P/CF): 12.50
• P/FCF Ratio: 12.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$11.75
• Price Target Upside: 13.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Biosyent showcases strong financial health and a promising earnings outlook, supported by strategic acquisitions and consistent shareholder returns. Although technical analysis indicates a potential downtrend, the company's stable valuation and positive corporate events provide a solid foundation for future growth. Key risks include challenges in the legacy and international segments, but overall, Biosyent is well-positioned in the pharmaceutical industry.

Positive Factors

Asset Acquisition

BioSyent announced the acquisition of the global rights to Tibella (Tibolone) for EUR 2.8M (~$4.24M CAD) from Mithra Pharmaceuticals SA and its subsidiary Novalon SA.

Financial Performance

BioSyent reported results that exceeded estimates.

Negative Factors

Asset Quality

No physical assets such as production plants or employees were acquired.

Revenue

The topline came in a bit below estimates.

Biosyent Business Overview & Revenue Model

Company Description

Biosyent Inc. (RX) is a Canadian specialty pharmaceutical company that focuses on the development and commercialization of innovative pharmaceutical and healthcare products. The company primarily operates in the sectors of health science and pharmaceuticals, offering a diverse range of prescription and over-the-counter products. Biosyent's core products include pharmaceuticals for the treatment of iron deficiency, women's health, and urology, as well as other therapeutic areas.

How the Company Makes Money

Biosyent Inc. generates revenue primarily through the sale of its pharmaceutical products to healthcare providers, pharmacies, and distributors. The company leverages its expertise in commercializing niche healthcare products across Canada and other international markets. Key revenue streams include prescription sales and over-the-counter product sales. Additionally, Biosyent may engage in strategic partnerships and licensing agreements to expand its product offerings and market reach, contributing to its overall earnings. The company focuses on identifying underutilized or novel products that address unmet medical needs, allowing it to capture market share and drive revenue growth.

Biosyent Financial Statement Overview

Summary

Biosyent presents strong financial performance with robust revenue growth and profit margins. The balance sheet is particularly strong, with low leverage and high equity ratios. However, the cash flow indicates a need for improvement in free cash flow conversion.

Income Statement

Biosyent shows strong performance in its income statement with a consistent revenue growth trajectory and healthy profit margins. The gross profit margin is robust at approximately 78.7% TTM, and the net profit margin stands at 20.6% TTM, indicating efficient cost management. Revenue growth is positive at 9.2% from the previous year, reflecting solid market demand. EBIT and EBITDA margins are also strong, at 23.9% and 28.7% respectively, showcasing good operational efficiency. However, the growth rate is moderate, which could be an area for improvement.

Balance Sheet

The balance sheet of Biosyent is very strong, with a low debt-to-equity ratio of 0.03 TTM, indicating minimal leverage and financial risk. The company maintains a high equity ratio of 82.1% TTM, which highlights an excellent capital structure and financial stability. The return on equity is also commendable at 19.0% TTM, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects a solid financial position with low risks.

Cash Flow

Biosyent's cash flow statement indicates good operating cash flow, with an operating cash flow to net income ratio of 1.01 TTM, demonstrating effective cash generation. However, the free cash flow has decreased significantly, resulting in a negative free cash flow growth rate, which could be a concern for long-term sustainability. The free cash flow to net income ratio is relatively low at -0.01 TTM, suggesting potential issues in converting profits to free cash flow. Attention is needed to improve cash conversion efficiency.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
34.51M	31.59M	27.93M	28.62M	22.33M	21.42M
	Gross Profit
27.17M	25.60M	22.86M	22.64M	17.42M	16.65M
	EBIT
8.26M	7.47M	6.98M	8.18M	5.03M	5.39M
	EBITDA
9.92M	9.06M	7.96M	8.92M	5.84M	6.19M
	Net Income Common Stockholders
7.11M	6.46M	5.46M	6.28M	3.80M	4.37M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
24.43M	26.19M	28.70M	28.21M	25.58M	21.97M
	Total Assets
31.19M	41.53M	40.49M	37.17M	33.57M	30.97M
	Total Debt
0.00	1.22M	1.40M	1.56M	1.71M	1.85M
	Net Debt
-16.83M	-6.76M	-6.47M	-16.48M	-18.58M	-11.59M
	Total Liabilities
3.58M	6.77M	7.12M	5.61M	6.78M	5.17M
	Stockholders Equity
27.61M	34.76M	33.36M	31.55M	26.80M	25.79M
Cash Flow		Free Cash Flow
-87.30K	4.88M	4.43M	4.58M	6.72M	4.04M
	Operating Cash Flow
7.19M	5.05M	4.95M	4.67M	6.89M	4.77M
	Investing Cash Flow
1.02M	883.85K	-10.79M	-4.84M	3.39M	-1.68M
	Financing Cash Flow
-4.92M	-5.78M	-4.37M	-2.08M	-3.37M	-6.39M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Negative. The current price of 10.39 is below the 20-day moving average (MA) of 10.55, below the 50-day MA of 10.85, and below the 200-day MA of 10.80, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 46.37 is Neutral, neither overbought nor oversold. The STOCH value of 45.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	78 Outperform	C$118.04M	16.40	20.84%	1.80%	10.89%	16.21%
NEO	67 Neutral	C$423.68M	―	-3.15%	3.95%	-15.41%	-69.47%
GUD	65 Neutral	$568.85M	131.14	0.53%	―	13.13%	―
HLS	54 Neutral	C$135.12M	―	-23.20%	―	-8.80%	26.77%
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%

Biosyent Corporate Events

BioSyent to Participate in Planet MicroCap Showcase 2025

BioSyent Inc. has announced its participation in the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas, where President and CEO René Goehrum will present and meet with investors. This participation highlights BioSyent’s active engagement with the investment community, potentially enhancing its market visibility and investor relations.

Spark’s Take on TSE:RX Stock

According to Spark, TipRanks’ AI Analyst, TSE:RX is a Outperform.

BioSyent’s overall score reflects its strong financial performance and positive earnings call, supported by strategic growth initiatives and shareholder-friendly practices. Technical analysis indicates potential near-term challenges, but the stock remains fundamentally solid with reasonable valuation metrics and attractive dividend yield.

To see Spark’s full report on TSE:RX stock, click here.

BioSyent to Present at LD Micro Investor Conference

BioSyent Inc. announced that its President and CEO, René Goehrum, will present at the LD Micro Invitational XV Conference in New York City on April 10, 2025. This presentation and subsequent one-on-one meetings with investors highlight BioSyent’s proactive approach to engaging with stakeholders and promoting its growth-oriented pharmaceutical business.

FeraMAX® Tops Canadian Iron Supplement Recommendations for Tenth Year

BioSyent Inc. announced that its FeraMAX® brand has been named the #1 recommended iron supplement in Canada for the tenth consecutive year by pharmacists and physicians. This recognition underscores the brand’s leadership in iron health and its commitment to expanding its range of products to treat and prevent iron deficiency across all life stages. The recognition is based on a national survey that highlights the role of healthcare professionals in recommending over-the-counter products, reinforcing BioSyent’s strong market positioning and trust among Canadian healthcare providers.

BioSyent Grants Restricted Share Units to Key Personnel

BioSyent Inc. has announced the approval of a grant of 56,767 Restricted Share Units (RSUs) to certain directors, officers, management, and employees as part of its Restricted Share Unit Plan. These RSUs will fully vest within three years, potentially enhancing employee retention and aligning their interests with the company’s growth objectives. This move reflects BioSyent’s commitment to rewarding its team and could positively impact its operations by motivating key personnel.

BioSyent Inc. Achieves Record Growth and Expands Global Reach in 2024

BioSyent Inc. reported strong financial results for the fourth quarter and full year 2024, with significant growth in Canadian pharmaceutical sales and a notable increase in EBITDA and net income. The acquisition of global rights to Tibelia® (tibolone) and the transition of its distribution to BioSyent’s structure are expected to diversify revenue streams and enhance profitability. The company also maintained its commitment to shareholders by returning $7.3 million through dividends and share buybacks, marking its 15th consecutive year of profitability.